Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nucresiran - Alnylam Pharmaceuticals

Next Previous
Drug Profile

Nucresiran - Alnylam Pharmaceuticals

Alternative Names: ALN-TTRsc04

Latest Information Update: 10 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Prealbumin expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transthyretin-related hereditary amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Transthyretin-related hereditary amyloidosis

Most Recent Events

  • 25 Feb 2025 Alnylam Pharmaceuticals plans phase-III TRITON-CM/TRITON-PM trial for Transthyretin-related hereditary amyloidosis (SC)
  • 12 Jan 2025 Alnylam Pharmaceuticals plans the phase III TRITON-CM trial for Cardiomyopathy in first half of 2025 (SC)
  • 31 Dec 2024 Nucresiran - Alnylam Pharmaceuticals receives Orphan Drug status for Transthyretin-related hereditary amyloidosis in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top